Two Oncologics Face Tough ODAC Review: Problems Of Efficacy For Schering's PegIntron And Safety For GSK's Votrient
This article was originally published in The Pink Sheet Daily
The Oncologic Drugs Advisory Committee will meet Oct. 5 to evaluate the sNDA for PegIntron to treat melanoma and the NDA for Votrient to treat renal cell carcinoma.
You may also be interested in...
The panel voted 6-4 to recommend approval of the sBLA for PegIntron (peginterferon alfa-2b) for melanoma, and unanimously for Glaxo's Votrient (pazopanib) for advanced renal cell carcinoma.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.